≥99% for sensitive chromatographic and analytical workflows requiring minimal baseline interference.
Protected from light,Argon charged,Desiccated,Store at -80°C Ships Dry ice packs + Cold packs Check lot-specific COA for exact specifications.
SDS, COA, datasheet, and spec sheet available for download. Lot-specific COA accessible via lot number lookup.
Cited in 0 peer-reviewed publications across chromatography, organic synthesis, and cross-coupling reactions.
Retatrutide (LY3437943) is a triple agonist peptide of the Glukagon receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and Glukagon-like peptide-1 receptor (GLP-1R) . Retatrutide inhibits human GCGR , GIPR, and GLP-1R with EC 50 values of 5.79, 0.0643 and 0.775 nM, respectively. Retatrutide can be used for the research of obesity
In Vitro
Retatrutide (LY3437943) has efficacy for human GCGR, GIPR, and GLP-1R with EC 50 values of 5.79, 0.0643 and 0.775 nM, respectively. Retatrutide has efficacy for mouse GCGR, GIPR, and GLP-1R with EC 50 values of 2.32, 0.191 and 0.794 nM, respectively. Retatrutide has binding affinity for human GCGR, GIPR, and GLP-1R with K i values of 5.6, 0.057 and 7.2 nM, respectively. Retatrutide has binding affinity for mouse GCGR, GIPR, and GLP-1R with K i values of 73, 2.8 and 1.3 nM, respectively. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Retatrutide (LY3437943) (s.c.; 0.47 mg/kg; single) engages GCGR in vivo and can improve glucose tolerance in an ipGTT through either the GIP or GLP-1 receptors . Retatrutide (s.c.; 10 mL/kg; cycle every 3 days; for 21 days) causes great body weight loss and increases energy expenditure through Glukagon receptor activatio . Retatrutide has safety and tolerability . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Male CD-1 mice Dosage: 0.47 mg/kg Administration: Subcutaneous administration, single Result: AUC last , ng*h/mL AUC 0-∞ , ng*h/mL C max , ng/mL T max , h t 1/2 , h CLF, mL/h/kg 41135 41905 1680 12 21 11.22 Animal Model: Diet-induced obese (DIO) male C57/Bl6 mice (24-25 weeks, 40-51 g) Dosage: 10 mL/kg Administration: Subcutaneous (SC) injection, cycle every 3 days, for 21 days Result: Decreased body weight and improved glycemic control.
Form:Solid
IC50& Target:EC50 (for human): 5.79 (GCGR), 0.0643 (GIPR), 0.775 nM (GLP-1R),EC50 (for mouse): 2.32 (GCGR), 0.191 (GIPR), 0.794 nM (GLP-1R),Ki (for human): 5.6 (GCGR), 0.057 (GIPR), 7.2 nM (GLP-1R),Ki (for mouse): 73 (GCGR), 2.8 (GIPR), 1.3 nM (GLP-1R)
| Molecular Weight | 4731.33 |
|---|
Comprehensive hazard, handling, storage, and regulatory compliance document.
Download SDS →Lot-specific quality data. Enter your lot number to retrieve the exact COA.
Look up COA →Full quality attributes and acceptance criteria for this grade.
View spec sheet →| Solubility | H2O : 33.33 mg/mL (7.04 mM; ultrasonic and adjust pH to 7 with NaOH) |
|---|
